The potencies of the major neuroleptics used in the treatment of schizophrenia, including haloperidol and remoxipride, correlate with their ability to bind D2-dopaminergic receptors in subcortical structures. On the other hand, the neuroleptic clozapine has a low affinity for these sites, and the pharmacological basis of its beneficial action is less clear. We have found that chronic treatment with clozapine, haloperidol, and remoxipride up-regulates D2 receptors in specific cortical areas of the rhesus monkey frontal, parietal, temporal, and occipital lobes. Of particular interest, all three neuroleptics down-regulated D1 receptors in prefrontal and temporal association regions-the two areas most often associated with schizophrenia. This latter finding raises the possibility that down-regulation of D1 receptors in prefrontal and temporal cortex may be an important component of the therapeutic response to neuroleptic drugs. Further, the common effects of three neuroleptics with different pharmacological profiles in the cerebral cortex is consistent with the idea that this structure is a major therapeutic target in the treatment of schizophrenia.
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The therapeutic effect of neuroleptics has generally been associated with their binding to the D2 class of dopaminergic receptors in the brain (1) . However, the beneficial actions of clozapine have not been satisfactorily explained, given that this drug does not interact with D2 sites in most regions examined (2, 3) . Numerous previous studies of the effects of prolonged neuroleptic treatment on dopaminergic receptors have focused on subcortical structures (3) (4) (5) (6) (7) (8) , while the regulation of cerebral cortical dopaminergic sites by similar treatment has received little attention. Such data are particularly important in view of the mounting evidence for the involvement of the cortical dopaminergic system in schizophrenia (for reviews see refs. 9 and 10). To gain further insight into the mechanism of action of clozapine, we compared its effect on dopamine receptors in the cerebral cortex of rhesus monkeys with those of two representative neuroleptics, haloperidol and remoxipride. Both of these drugs display a high affinity for the D2-dopaminergic receptor sites in the neostriatum and nucleus accumbens, though remoxipride is more selective (11) .
MATERIALS AND METHODS
Sixteen rhesus monkeys (Macaca mulatta), 5-7 years of age, were divided into four groups of equal size. Group H received haloperidol (0.2 mg/kg per day), group C1 received clozapine (5.2 mg/kg per day), and group R received remoxipride (3.7 mg/kg per day). These doses fall within the recommended range for therapeutic effects in schizophrenic patients (12, 13) . The drugs were given orally (in fruit treats) twice a day for 6 months to approximate the maintenance of medication in clinical practice (14) . A control group (group CO) received only fruit treats. Five days after final administration ofdrugs, the animals were sacrificed, and cortical dopamine receptors were assayed by quantitative receptor autoradiography. The cortical regions examined are shown in Fig. 1A 
RESULTS AND DISCUSSION
Saturation analysis of [1251] epidepride binding showed that all three neuroleptics produced statistically significant increases (47-52%) in the density of D2-dopaminergic receptor sites in all layers of the temporal association, primary motor, sOmatosensory, and primary visual cortical regions (Fig. 3A) . D2 receptor sites were also increased in the prefrontal cortex but by a smaller percentage (11-18%) which did not reach statistical significance (Fig. 3A) (3) (4) (5) (6) (7) . However, the up-regulation of cortical D2 receptors by clozapine in widespread areas of the cerebral cortex differs from the apparent lack of such effect of clozapine on these sites in striatum and the nucleus accumbens (3) (4) (5) . An increase in the density of D2 receptors in response to clozapine treatment has also been observed in the medial prefrontal cortex ofthe rat (19) . It is ofinterest that the prefrontal cortex was the only area in our study where the D2 receptor was least affected by neuroleptics, including clozapine, perhaps indicating a difference between primates and rodents. The similarity in the effects of clozapine, haloperidol, and remoxipride on cortical D2-dopaminergic receptors may be related to the unique pharmacological and electrophysiological properties of the dopamine neurons that project to the cerebral cortex as compared with those of the nigrostriatal and mesolimbic dopamine systems (20) . Also, the cortex has a substantial proportion of the D4 subtype of the family of D2 receptors (21) , whereas the striatum and nucleus accumbens contain mainly D2A sites (22) . Clozapine has a high affinity for the D4 receptor subtype (21) and could easily up-regulate it, while the regulation of D2A receptors by clozapine would be negligible due to its low affinity for these sites (21) . Indeed, our preliminary binding studies in cell cultures expressing D4-dopaminergic receptors indicate that under the conditions of the present experiment, [125I]epidepride may label D4 sites (M.S.L., unpublished results). However, it remains to be determined whether the general increase in the density of the D2 sites in cortical areas described here is related in any way to the unique composition of D2 dopaminergic receptor subtypes in the cortex.
A major finding that could not have been predicted is that all three neuroleptics produced decreases in the density of D1-dopaminergic receptor sites. These reductions were substantial (30-34%) and were found exclusively in the prefrontal and temporal association cortices (Fig. 3B) and affected all layers of these cortical areas (Fig. 4) . No significant effects were observed in the somatosensory, visual, or motor areas (Fig. 3B) This, however, was not the case ( Table 1) .
The mechanisms for decrease in the density of cortical D1-dopaminergic receptor sites by chronic neuroleptic treatment are now open for investigation. For example, downregulation of D1 sites may be a compensatory reaction to a chronic increase in cortical dopamine release resulting from the blockade of D2 pre-and postsynaptic sites by neuroleptic drugs (23, 24) . It should be mentioned, however, that the effect of chronic neuroleptic treatment on cortical dopaminergic release after treatments as prolonged as that used in the present study is not presently known. It is possible, therefore, that very prolonged exposure to neuroleptics may produce depolarization block of the cortical dopaminergic innervation (25) . Depolarization block can also downregulate D1 receptors (26) , although this down-regulation would be related to the elimination of phasic dopamine release (27) . Alternatively, the decrease in D, receptor density may be secondary to a neuroleptic-induced increase in the level of responsiveness of D2-mediated adenylate cyclase to dopamine (6) . As a strong interaction between D1 and D2 second messenger systems is well established (28, 29) , it is conceivable that an increase in the sensitivity of D2-associated adenylate cyclase would be accompanied by an increase in the sensitivity of the D1-coupled enzyme which, in turn, would downregulate D1 receptors (8, 30) .
Our findings that haloperidol, remoxipride, and clozapine have virtually identical effects in all cortical areas examined may provide the missing link in understanding the therapeutic actions of these very different neuroleptic drugs. It seems particularly relevant that the D1 down-regulation was found selectively in the prefrontal and temporal cortical regions which, in rhesus monkeys, have especially high concentrations of dopamine receptors among cortical areas studied (31) . In humans, these areas are also critically involved in cognitive and affective functions (for review see refs. 32 and 33) and are the areas most often compromised in schizophrenia (9, 34, 35) . All of these considerations suggest that the D, receptors in these regions may be one of the major sites to which neuroleptic treatment is and/or should be directed.
Note Added in Proof. Since this paper was submitted for publication, an article by Malmberg et al. (36) came to our attention. It shows that clozapine binds to the short isoform of the D2A-dopaminergic receptor with an affinity comparable to that for D4 receptors. It has also been shown (37) that while the majority of the striatal D2A receptors belong to the long type, the short isoform is predominant among D2A receptors in the cerebral cortex (particularly in those areas where we detected neuroleptic-induced increase in D2A receptors). Thus, the clozapine-induced up-regulation of D2 sites, detected in the present study, may reflect an interaction of this drug with the D4 receptor, the short isoform of the D2A receptor, or both.
